tirzepatide shortage update today Update: On December 19th the FDA ruled the tirzepatide was resolved, however is giving a grace period for compounding pharmacies to continuing manufacturing. This grace period is 60 days. On The Tirzepatide Shortage Is Over:

Important Considerations When deciding where to inject tirzepatide, consider a few key factors: Rotate Injection Sites: Regularly switching the injection site helps reduce the risk of developing scars or fat deposits under the skin, known as lipodystrophy

Save on Tirzepatide treatment with Medicare Through the Medicare GLP-1 Bridge Program or our flat-rate compounded option, MDWatch delivers more clinical support than most national telehealth brands

The FDA-approved injectable form (Zepbound) has been studied in large clinical trials and shown to produce significant, sustained weight loss

Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial

Originally for type 2 diabetes management, it has gained significant attention for its substantial weight loss effects, making it a potential breakthrough for obesity-related conditions, including sleep apnea